Basis: FMP quote price / unrounded FMP forward EPS in the trading currency, available after its recorded retrieval time. Source: stored company filings and market data; unavailable inputs remain N/A.
The forward PE ratio is N/A as of 2026-10-06T15:43:03.621Z.
Consensus retrieved: 2026-10-06T14:43:01.171Z. This records retrieval, including cache reads, rather than vendor publication. The calculation uses the separately dated price and estimate available at its as-of time.
Calculation as of: 2026-10-06T15:43:03.621Z.
Quote observation: 2026-10-06T15:40:20.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 67e5dd0da90b5c88af523c31c194b361a7c32b17475a8585f92ae19a33da913a
Forward PE Ratio (N/A) = Dated Quote Price ($9.53) / Consensus Forward EPS ($-1.17)
FORWARD PE RATIO
N/A
Orthofix Medical Inc.
Market Cap
$385.22M
Forward PE Ratio
N/A
| NAME | MARKET CAP | FORWARD PE RATIO |
|---|---|---|
| Orthofix Medical Inc. (OFIX) | $385.22M | N/A |
| Arcturus Therapeutics Holdings Inc. (ARCT)vs › | $381.44M | N/A |
| Kyverna Therapeutics, Inc. (KYTX)vs › | $389.09M | N/A |
| Canopy Growth Corporation (CGC)vs › | $374.16M | N/A |
| MapLight Therapeutics, Inc. (MPLT)vs › | $395.51M | N/A |
| Myriad Genetics, Inc. (MYGN)vs › | $401.26M | N/A |
| Carlsmed, Inc. (CARL)vs › | $402.07M | N/A |
| Opus Genetics, Inc. (IRD)vs › | $363.23M | N/A |
| Ocugen, Inc. (OCGN)vs › | $361.15M | N/A |
| Shoulder Innovations, Inc. (SI)vs › | $409.89M | N/A |
Trailing P/E
N/A
reported TTM EPS
Forward P/E
N/A
consensus EPS · fiscal year ending 2026-12-31
At the dated quote price of $9.53, each upcoming fiscal year's consensus EPS implies a different multiple — how quickly the price is "paid down" by expected earnings if the estimates hold.
| Fiscal year end | Consensus EPS | Estimate range | Analysts | Implied P/E |
|---|---|---|---|---|
| 2026-12-31 | $-1.18 | $-1.19 – $-1.16 | 1 | n/m |
| 2027-12-31 | $-0.94 | $-0.95 – $-0.93 | 1 | n/m |
| 2028-12-31 | $-0.64 | $-0.79 – $-0.49 | 2 | n/m |
Source: FMP analyst consensus estimates, refreshed with the daily precompute. "n/m" = the consensus EPS is not positive, so a multiple is undefined. There is no forward P/E history chart here because charting one would require the estimates as they stood in the past, which we do not store — see the trailing P/E history for how the realized multiple has moved.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
